Clinical Trial Search

Primary: Percentage of Those Maintain or Improve to HIV RNA-1 Viral Load Less Then 400 Copies/mL — 54; 42 percent of participants

Primary: Number of Participants With Treatment-emergent Serious Adverse Event (SAE) and Adverse Event (AE) — 48; 173 Participants

Primary: Number of Participants With no Serious Adverse Events — 5 participants

Primary: PTSD Checklist (PCL). A Self-report, Face Valid Measure of PTSD Symptoms Over a 1 Week Time Period — 55.76; 54.83; 50.14; 51.57 units on a scale

Primary: Progression-free Survival. Progression is Defined According WHO-criteria as Appearance of Any New Lesion or Increase of Existing Lesions by at Least 25% — 28.8 months

Primary: Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization…

Primary: Attention Deficit Hyperactivity Disorder- Rating Scale (ADHS-RS) — 13.9 units on a scale — p=0.001

Primary: Mean Concentration of Vancomycin in Subcutaneous Fat — 94.1; 3.2; 88.3; 5.0 µg/g — p=<0.0001

Primary: Delivery Rate — 31; 21 participants

Primary: Nightly CPAP Use — 6.4; 5.8 hours/night — p=0.20

Primary: Part 1: Percentage of Participants With Adverse Events (AEs) — 95.5; 100.0 percentage of participants

Primary: Tinnitus Functional Index — 69.9; 68.2; 47.8; 66.8 units on a scale — p=<.0001

Primary: Percentage of Participants With Undetectable HCV RNA Who Achieve Sustained Viral Response at Follow-up Week 12 (SVR12) [16-Week Arm vs. 28-Week Arm] — 70.6; 81.9…

Primary: Severity of Pulmonary Complications in the Post-operative Period — 15; 26 percentage of participants — p=0.016

Primary: In Hospital Mortality — 0; 4 participants — p=0.142